X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (2530) 2530
life sciences & biomedicine (2395) 2395
humans (2231) 2231
animals (1607) 1607
male (1440) 1440
thiazoles - pharmacokinetics (1347) 1347
pharmacology & pharmacy (1146) 1146
thiazoles - pharmacology (1074) 1074
female (960) 960
thiazoles - therapeutic use (835) 835
thiazoles - administration & dosage (756) 756
rats (658) 658
adult (547) 547
mice (523) 523
thiazoles - chemistry (513) 513
middle aged (490) 490
thiazoles - adverse effects (487) 487
administration, oral (465) 465
dose-response relationship, drug (412) 412
thiazoles - blood (352) 352
aged (345) 345
chemistry (322) 322
physical sciences (304) 304
pharmacokinetics (287) 287
oncology (279) 279
thiazoles (273) 273
analysis (272) 272
thiazoles - metabolism (272) 272
rats, sprague-dawley (269) 269
meloxicam (266) 266
drug interactions (241) 241
treatment outcome (234) 234
neurosciences & neurology (229) 229
structure-activity relationship (227) 227
biochemistry & molecular biology (221) 221
cell line, tumor (221) 221
dasatinib (219) 219
area under curve (202) 202
half-life (198) 198
thiazines - pharmacokinetics (192) 192
research (188) 188
thiazolidinediones (187) 187
chemistry, medicinal (185) 185
drug therapy (184) 184
dogs (183) 183
neurosciences (183) 183
thiazoles - chemical synthesis (181) 181
pharmacology/toxicology (177) 177
thiazines - administration & dosage (177) 177
biological availability (175) 175
time factors (175) 175
medicine & public health (174) 174
tetrazolium salts (167) 167
double-blind method (161) 161
abridged index medicus (159) 159
toxicology (158) 158
veterinary sciences (157) 157
hematology (155) 155
anti-inflammatory agents, non-steroidal - pharmacokinetics (152) 152
care and treatment (152) 152
molecular structure (152) 152
adolescent (146) 146
young adult (145) 145
chromatography, high pressure liquid (139) 139
anti-inflammatory agents, non-steroidal - administration & dosage (138) 138
pyridines - therapeutic use (137) 137
rats, wistar (137) 137
aged, 80 and over (135) 135
cancer (135) 135
cell survival - drug effects (135) 135
cell line (134) 134
antineoplastic agents - pharmacology (133) 133
pyridines - pharmacokinetics (132) 132
piperazines - therapeutic use (130) 130
tissue distribution (130) 130
chemistry, multidisciplinary (128) 128
kinetics (128) 128
pharmacology (127) 127
dosage and administration (122) 122
research article (121) 121
brain - metabolism (120) 120
pyridines - administration & dosage (119) 119
cross-over studies (118) 118
pyrimidines - therapeutic use (118) 118
drug administration schedule (115) 115
in vitro techniques (115) 115
disease models, animal (114) 114
biomedicine (113) 113
pyridines - pharmacology (112) 112
piperazines - pharmacokinetics (111) 111
science & technology - other topics (111) 111
drug therapy, combination (110) 110
clinical neurology (109) 109
hypoglycemic agents - pharmacokinetics (109) 109
cardiovascular system & cardiology (107) 107
thiazines - pharmacology (107) 107
protein binding (106) 106
psychiatry (106) 106
anticoagulants (105) 105
cells, cultured (105) 105
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3273) 3273
Japanese (34) 34
German (25) 25
Chinese (7) 7
Russian (7) 7
French (5) 5
Danish (3) 3
Dutch (3) 3
Spanish (3) 3
Croatian (1) 1
Hungarian (1) 1
Italian (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical Pharmacology & Therapeutics, ISSN 0009-9236, 03/2010, Volume 87, Issue 3, pp. 322 - 329
Journal Article
Cancer Treatment Reviews, ISSN 0305-7372, 2009, Volume 35, Issue 8, pp. 692 - 706
.... Post marketing study commitments have been made upon (accelerated) approval such as additional pharmacokinetic studies in patients with renal- or hepatic impairment... 
Hematology, Oncology and Palliative Medicine | Excretion | Absorption | Metabolism | Tyrosine kinase inhibitors | Distribution | Drug transporters and interactions | Life Sciences & Biomedicine | Oncology | Science & Technology | Erlotinib Hydrochloride | Niacinamide - analogs & derivatives | Pyrroles - pharmacokinetics | Humans | Cytochrome P-450 Enzyme System - metabolism | Pyridines - pharmacokinetics | Quinazolines - pharmacokinetics | Biological Availability | Phenylurea Compounds | Antineoplastic Agents - administration & dosage | Intestinal Absorption | Thiazoles - pharmacokinetics | Antineoplastic Agents - metabolism | Tissue Distribution | Benzenesulfonates - pharmacokinetics | Drug Interactions | Antineoplastic Agents - pharmacokinetics | Antineoplastic Agents - pharmacology | Piperazines - pharmacokinetics | Protein Kinase Inhibitors - pharmacokinetics | Dasatinib | Administration, Oral | Imatinib Mesylate | Protein Kinase Inhibitors - blood | Protein Kinase Inhibitors - administration & dosage | Antineoplastic Agents - blood | Pyrimidines - pharmacokinetics | Indoles - pharmacokinetics | Protein Kinase Inhibitors - pharmacology | Benzamides | Protein Kinase Inhibitors - metabolism | Protein-Tyrosine Kinases - antagonists & inhibitors | Tyrosine | Care and treatment | Oncology, Experimental | Cytochrome P-450 | Physiological aspects | Phenols | Research | Phosphotransferases | Protein binding | Cancer | Index Medicus
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 06/2016, Volume 67, Issue 24, pp. 2888 - 2899
... dialysis. The authors review the current pharmacokinetic, observational, and prospective data on NOACs in patients with advanced chronic kidney disease... 
Cardiovascular | Internal Medicine | dabigatran | rivaroxaban | apixaban | stroke | edoxaban | renal dialysis | Cardiac & Cardiovascular Systems | Life Sciences & Biomedicine | Cardiovascular System & Cardiology | Science & Technology | Pyrazoles - therapeutic use | Dabigatran - pharmacokinetics | Humans | Pyridines - pharmacokinetics | Renal Insufficiency, Chronic - complications | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - pharmacokinetics | Warfarin - therapeutic use | Renal Insufficiency, Chronic - therapy | Kidney - metabolism | Pyrazoles - pharmacokinetics | Rivaroxaban - therapeutic use | Pyridines - therapeutic use | Stroke - prevention & control | Glomerular Filtration Rate | Pyridones - pharmacokinetics | Atrial Fibrillation - drug therapy | Anticoagulants - therapeutic use | Creatinine - urine | Warfarin - pharmacokinetics | Kidney Failure, Chronic - therapy | Rivaroxaban - pharmacokinetics | Kidney Failure, Chronic - complications | Anticoagulants - pharmacokinetics | Pyridones - therapeutic use | Hemorrhage - chemically induced | Renal Dialysis | Stroke (Disease) | Medical colleges | Care and treatment | Continuing medical education | Warfarin | Chronic kidney failure | Atrial fibrillation | Mortality | Medical care | Quality management | Urine | Confidence intervals | Disease prevention | Anticoagulants | Stroke | Hemodialysis | Kidney diseases | Metabolism | Drug dosages | Index Medicus | Abridged Index Medicus
Journal Article
Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 10/2006, Volume 33, Issue 10, pp. 917 - 924
...)-2-selective NSAIDs is linked to their pharmacokinetics. • A single oral dose of rofecoxib (10 mg/kg), celecoxib (40 mg/kg), meloxicam (3 mg/kg) or placebo was administered to rats... 
pharmacokinetics | kidney | non-steroidal anti-inflammatory drugs | cyclo-oxygenase-2 | sodium urinary excretion | cyclo‐oxygenase‐2 | non‐steroidal anti‐inflammatory drugs | Cyclo-oxygenase-2 | Pharmacokinetics | Kidney | Non-steroidal anti-inflammatory drugs | Sodium urinary excretion | Pharmacology & Pharmacy | Physiology | Life Sciences & Biomedicine | Science & Technology | Thiazoles - blood | Area Under Curve | Thiazines - administration & dosage | Thiazines - adverse effects | Sulfones - adverse effects | Male | Thiazoles - administration & dosage | Anti-Inflammatory Agents, Non-Steroidal - blood | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Dose-Response Relationship, Drug | Cyclooxygenase 2 Inhibitors - adverse effects | Sulfonamides - blood | Lactones - blood | Lactones - pharmacokinetics | Sodium - urine | Lactones - administration & dosage | Pyrazoles - blood | Pyrazoles - pharmacokinetics | Sulfones - blood | Placebos - administration & dosage | Pyrazoles - adverse effects | Thiazines - pharmacokinetics | Kidney - drug effects | Administration, Oral | Cyclooxygenase 2 Inhibitors - administration & dosage | Rats | Thiazines - blood | Celecoxib | Lactones - adverse effects | Placebos - pharmacokinetics | Sulfones - pharmacokinetics | Cyclooxygenase 2 Inhibitors - pharmacokinetics | Rats, Sprague-Dawley | Sulfonamides - pharmacokinetics | Pyrazoles - administration & dosage | Animals | Anti-Inflammatory Agents, Non-Steroidal - adverse effects | Potassium - urine | Anti-Inflammatory Agents, Non-Steroidal - pharmacokinetics | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Sulfones - administration & dosage | Kidney, drug effects | Lactones, adverse effects | Sulfones, administration and dosage | Thiazoles, administration and dosage | Anti-Inflammatory Agents, Non-Steroidal, pharmacokinetics | Anti-Inflammatory Agents, Non-Steroidal, adverse effects | Sodium, urine | Thiazines, blood | Anti-Inflammatory Agents, Non-Steroidal, blood | Lactones, administration and dosage | Cyclooxygenase 2 Inhibitors, adverse effects | Pyrazoles, blood | Sulfonamides, pharmacokinetics | Thiazines, pharmacokinetics | Pyrazoles, administration and dosage | Thiazoles, blood | Sulfonamides, administration and dosage | Cyclooxygenase 2 Inhibitors, administration and dosage | Lactones, pharmacokinetics | Sulfonamides, blood | Cyclooxygenase 2 Inhibitors, pharmacokinetics | Thiazines, adverse effects | Lactones, blood | Thiazoles, adverse effects | Thiazoles, pharmacokinetics | Sulfones, blood | Sulfonamides, adverse effects | Thiazines, administration and dosage | Placebos, pharmacokinetics | Sulfones, pharmacokinetics | Pyrazoles, adverse effects | Placebos, administration and dosage | Potassium, urine | Sulfones, adverse effects | Pyrazoles, pharmacokinetics | Index Medicus
Journal Article
Journal Article